SCHEDULE: State Street Reports 5.5% Stake in Viridian Therapeutics

State Street Corporation has disclosed beneficial ownership of 5.5% of Viridian Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• State Street Corporation, through its subsidiaries, now beneficially owns 6,124,976 shares of Viridian Therapeutics Inc. common stock.
• This ownership represents 5.5% of the total class of securities.
• The filing indicates shared voting power of 5,894,254 shares and shared dispositive power for 6,124,976 shares.
• The reporting date for this ownership stake is June 30, 2026.
• The filing is made under Schedule 13G, indicating passive investment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without indicating a significant shift in investment strategy or company performance.

Positives

• State Street Corporation's investment suggests confidence in Viridian Therapeutics' long-term prospects.
• A 5.5% stake is a significant holding, potentially indicating a stable institutional investor.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind the ownership level.
• The passive nature of the filing (Schedule 13G) means it does not signal an intent to influence or control the company.

Risks

• Market volatility could impact the value of the investment for State Street Corporation.
• Changes in Viridian Therapeutics' clinical trial progress or regulatory approvals could affect the stock price and, consequently, the value of State Street's holding.

Future Outlook

This filing is a snapshot of beneficial ownership as of a specific date and does not contain forward-looking statements or guidance from Viridian Therapeutics Inc.

Industry Context

StockSavvy.ai notes that institutional investors like State Street Corporation often build significant stakes in biotechnology companies like Viridian Therapeutics, especially during periods of development and potential growth, as indicated by the passive Schedule 13G filing.

Stakeholder Impact

• Shareholders: The filing indicates a significant institutional investor, which can be viewed positively for stability, but the passive nature means no immediate impact on control.
• Management: The passive stake suggests no immediate pressure for strategic changes from State Street Corporation.
• Creditors: No direct impact mentioned.

Next Steps

• State Street Corporation will continue to monitor Viridian Therapeutics Inc.'s performance and may adjust its holdings.
• Viridian Therapeutics Inc. will continue its operations and development activities.

Key Dates

Keywords

Viridian Therapeutics, State Street Corporation, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Holding